Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SELENADE: Lemborexant for Insomnia Comorbid with Depressive Episodes
jRCTs071220037Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of lemborexant in Insomnia, major depressive disorder (MDD) and bipolar disorder (BD) (3 cohorts), sponsored by Eisai Co., Ltd. Started Oct 2022; status: completed.
02
Drugs
lemborexant
03
Conditions
Insomniamajor depressive disorder (MDD)bipolar disorder (BD)
Beyond the preview
Go deeper on jRCTs071220037.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs071220037.